Of note, circulating prolactin is an established breast-cancer risk factor that has been confirmed in a series of analyses from the prospective Nurses’ Health Study, particularly with respect to ER-positive breast cancer [43], and a large analysis from the prospective EPIC cohort [44] with emphasis on users of hormone replacement therapy. The gene discussed is PRL; the disease is breast carcinoma.